Blinatumomab and asciminib for Ph+ ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia called Philadelphia chromosome-positive ALL (Ph+ ALL) or a related condition.
- You can be newly diagnosed (with little or no prior treatment) or have leukemia that has come back or not responded to treatment.
- You must be at least 12 years old and weigh at least 40 kg (about 88 pounds).
- You should be able to get out of bed and care for yourself (ECOG score 0-2 or Lansky score ≥50).
- Your liver, kidneys, pancreas, and heart must be working well enough (based on blood tests and physical exam).
- You cannot have a serious active infection, another active cancer, or a history of seizures or major brain problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—blinatumomab (an immune therapy) and olverembatinib (a targeted pill)—for people with a specific type of ALL that has the Ph chromosome or BCR::ABL1 gene. It aims to see if this combination works well in controlling the disease.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Hear when a new Philadelphia Chromosome Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.